Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, controlled, multicenter phase Ⅲ study to evaluate the therapeutic
efficacy and safety of chidamide + sintilimab + bevacizumab versus standard second-line
FOLFIRI + bevacizumab therapy in subjects with advanced microsatellite stable colorectal
cancer who have failed first-line oxaliplatin-containing standard therapy. The primary
purpose is to compare the progression-free survival (PFS) of chidamide + sintilimab +
bevacizumab versus standard second-line FOLFIRI + bevacizumab therapy for colorectal cancer,
with a planned enrollment of 176 subjects with advanced microsatellite stable colorectal
cancer who have failed first-line oxaliplatin-containing standard therapy.